Zacks Research Issues Pessimistic Estimate for RDY Earnings

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Stock analysts at Zacks Research lowered their FY2026 earnings per share (EPS) estimates for Dr. Reddy’s Laboratories in a report issued on Wednesday, February 12th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.79 per share for the year, down from their prior estimate of $0.80. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $0.80 per share. Zacks Research also issued estimates for Dr. Reddy’s Laboratories’ Q4 2026 earnings at $0.19 EPS and Q2 2027 earnings at $0.15 EPS.

A number of other research firms have also issued reports on RDY. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th. Nomura downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th. Finally, Barclays decreased their target price on Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th.

Dr. Reddy’s Laboratories Price Performance

NYSE RDY opened at $14.02 on Friday. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories has a 1 year low of $13.36 and a 1 year high of $16.89. The company has a market cap of $11.70 billion, a PE ratio of 22.32 and a beta of 0.50. The stock’s 50-day moving average price is $14.75 and its two-hundred day moving average price is $15.32.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%.

Hedge Funds Weigh In On Dr. Reddy’s Laboratories

Several institutional investors have recently bought and sold shares of the stock. Robeco Institutional Asset Management B.V. raised its position in shares of Dr. Reddy’s Laboratories by 453.8% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock valued at $180,620,000 after purchasing an additional 9,373,412 shares during the period. World Investment Advisors LLC bought a new position in Dr. Reddy’s Laboratories in the 3rd quarter worth approximately $3,459,000. Crossmark Global Holdings Inc. increased its position in Dr. Reddy’s Laboratories by 328.3% during the fourth quarter. Crossmark Global Holdings Inc. now owns 12,760 shares of the company’s stock worth $201,000 after acquiring an additional 9,781 shares during the period. Nordea Investment Management AB lifted its position in shares of Dr. Reddy’s Laboratories by 441.8% in the 4th quarter. Nordea Investment Management AB now owns 125,363 shares of the company’s stock worth $1,992,000 after acquiring an additional 102,226 shares during the period. Finally, Atomi Financial Group Inc. acquired a new stake in Dr. Reddy’s Laboratories during the fourth quarter valued at approximately $162,000. 3.85% of the stock is currently owned by institutional investors.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.